MHOs represent between 10% and 30% of people with obesity and exhibit low cardiometabolic risk (higher insulin sensitivity, normal blood pressure, lower lipid levels of triglycerides (TGs), low-density lipoproteins, and higher levels of high-density lipoproteins). This evidence concerns the gene INS and obesity disorder.